Tailoring stepwise treatment for Budd-Chiari syndrome: insights from the Asian Pacific Association for the Study of the Liver (APASL) consensus guidance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Early Radiological Intervention in Budd-Chiari Syndrome: Clinical Outcomes From a Single-Center Study.International journal of hepatology · 2026
   Article
2. Comparative efficacy and safety of endovascular intervention versus conservative therapy in Budd-Chiari syndrome: a retrospective cohort study.BMC gastroenterology · 2025
   Article
3. Triple Threat: SLE, APS, and Clotting Factor Abnormalities Leading to Subacute Budd-Chiari Syndrome. A Case Report and Review of the Literature.Clinical medicine insights. Case reports · 2025
   Article

Corrections and comments

• Comment on
  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).2021

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as